[go: up one dir, main page]

SG11201606209PA - Macrocycles with hetrocyclic p2' groups as factor xia inhibitors - Google Patents

Macrocycles with hetrocyclic p2' groups as factor xia inhibitors

Info

Publication number
SG11201606209PA
SG11201606209PA SG11201606209PA SG11201606209PA SG11201606209PA SG 11201606209P A SG11201606209P A SG 11201606209PA SG 11201606209P A SG11201606209P A SG 11201606209PA SG 11201606209P A SG11201606209P A SG 11201606209PA SG 11201606209P A SG11201606209P A SG 11201606209PA
Authority
SG
Singapore
Prior art keywords
hetrocyclic
macrocycles
groups
factor xia
xia inhibitors
Prior art date
Application number
SG11201606209PA
Inventor
James R Corte
Lucca Indawati De
Tianan Fang
Wu Yang
Yufeng Wang
Andrew K Dilger
Kumar Balashanmuga Pabbisetty
William R Ewing
Yeheng Zhu
Ruth R Wexler
Donald J P Pinto
Michael J Orwat
Leon M Ii Smith
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52484570&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201606209P(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of SG11201606209PA publication Critical patent/SG11201606209PA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compression Or Coding Systems Of Tv Signals (AREA)
SG11201606209PA 2014-01-31 2015-01-30 Macrocycles with hetrocyclic p2' groups as factor xia inhibitors SG11201606209PA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461933942P 2014-01-31 2014-01-31
US201462058293P 2014-10-01 2014-10-01
PCT/US2015/013654 WO2015116886A1 (en) 2014-01-31 2015-01-30 Macrocycles with hetrocyclic p2' groups as factor xia inhibitors

Publications (1)

Publication Number Publication Date
SG11201606209PA true SG11201606209PA (en) 2016-08-30

Family

ID=52484570

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201606209PA SG11201606209PA (en) 2014-01-31 2015-01-30 Macrocycles with hetrocyclic p2' groups as factor xia inhibitors
SG10201908467R SG10201908467RA (en) 2014-01-31 2015-01-30 Macrocycles with hetrocyclic p2' groups as factor xia inhibitors

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201908467R SG10201908467RA (en) 2014-01-31 2015-01-30 Macrocycles with hetrocyclic p2' groups as factor xia inhibitors

Country Status (32)

Country Link
US (2) US20170002006A1 (en)
EP (4) EP3099687B1 (en)
JP (6) JP6464176B2 (en)
KR (3) KR102631769B1 (en)
CN (4) CN110845498B (en)
AU (5) AU2015210904C1 (en)
BR (1) BR112016015717B1 (en)
CA (1) CA2937739C (en)
CL (1) CL2016001933A1 (en)
CY (1) CY1120702T1 (en)
DK (1) DK3099687T3 (en)
EA (1) EA030222B1 (en)
ES (3) ES2687498T3 (en)
HR (1) HRP20181339T1 (en)
HU (1) HUE040226T2 (en)
IL (5) IL298983B2 (en)
LT (1) LT3099687T (en)
MX (2) MX377545B (en)
MY (1) MY190429A (en)
NZ (2) NZ761182A (en)
PE (2) PE20161069A1 (en)
PH (2) PH12016501249B1 (en)
PL (1) PL3099687T3 (en)
PT (1) PT3099687T (en)
RS (1) RS57659B1 (en)
SG (2) SG11201606209PA (en)
SI (1) SI3099687T1 (en)
SM (1) SMT201800505T1 (en)
TW (4) TW201613922A (en)
UY (3) UY40230A (en)
WO (2) WO2015116886A1 (en)
ZA (1) ZA201606011B (en)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201116559D0 (en) 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
EP3309148A1 (en) 2011-10-14 2018-04-18 Bristol-Myers Squibb Company Substituted tetrahydroisoquinoline compounds as factor xia inhibitors
US9738655B2 (en) 2013-03-25 2017-08-22 Bristol-Myers Squibb Company Tetrahydroisoquinolines containing substituted azoles as factor XIa inhibitors
NO2760821T3 (en) 2014-01-31 2018-03-10
UY40230A (en) * 2014-01-31 2023-08-15 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Macrocycles with heterocyclic P2' groups as inhibitors of factor XIa and pharmaceutical compositions comprising them
EP2913330A1 (en) 2014-02-27 2015-09-02 Laboratoire Biodim Condensed derivatives of imidazole useful as pharmaceuticals
ES2714283T3 (en) 2014-09-04 2019-05-28 Bristol Myers Squibb Co Macrocycles of diamide that are inhibitors of FXIa
NO2721243T3 (en) * 2014-10-01 2018-10-20
SG11201702628XA (en) 2014-10-01 2017-04-27 Merck Patent Gmbh Boronic acid derivatives
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
JOP20160086B1 (en) 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development Mono- or di-substituted indole derivatives as dengue viral replication inhibitors
EP3310777B1 (en) 2015-06-19 2019-10-09 Bristol-Myers Squibb Company Diamide macrocycles as factor xia inhibitors
JO3703B1 (en) 2015-07-09 2021-01-31 Bayer Pharma AG Substituted oxopyridine derivatives
CN107849026B (en) * 2015-07-29 2021-01-01 百时美施贵宝公司 Factor XIA macrocycle inhibitors carrying alkyl or cycloalkyl P2' moieties
US10676477B2 (en) 2015-07-29 2020-06-09 Bristol-Myers Squibb Company Factor XIa macrocycle inhibitors bearing a non-aromatic P2' group
JOP20160198B1 (en) 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc Single or di-substituted indole derivatives as inhibitors of viral replication of fennel fever
JO3633B1 (en) 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development Single or binary substituted indole derivatives as inhibitors of viral replication of fennel fever
US10344039B2 (en) 2015-10-29 2019-07-09 Merck Sharp & Dohme Corp. Macrocyclic spirocarbamate derivatives as factor XIa inhibitors, pharmaceutically acceptable compositions and their use
US10214512B2 (en) * 2015-10-29 2019-02-26 Merck Sharp & Dohme Corp. Factor XIA inhibitors
EP3423458A1 (en) 2016-03-02 2019-01-09 Bristol-Myers Squibb Company Diamide macrocycles having factor xia inhibiting activity
KR102359743B1 (en) 2016-03-31 2022-02-07 얀센 파마슈티칼즈, 인코포레이티드 Substituted indole derivatives as inhibitors of dengue virus replication
KR102359735B1 (en) 2016-03-31 2022-02-08 얀센 파마슈티칼즈, 인코포레이티드 Substituted indoline derivatives as dengue virus replication inhibitors
SG11201808237UA (en) 2016-04-01 2018-10-30 Janssen Pharmaceuticals Inc Substituted indole compound derivatives as dengue viral replication inhibitors
JOP20170069B1 (en) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc Substituted indoline derivatives as dengue viral replication inhibitors
AR109304A1 (en) 2016-08-10 2018-11-21 Sumitomo Chemical Co OXADIAZOL COMPOUND AND ITS USE
EP3500556B1 (en) 2016-08-22 2023-08-02 Merck Sharp & Dohme LLC Pyridine-1-oxide derivatives and their use as factor xia inhibitors
WO2018133793A1 (en) * 2017-01-18 2018-07-26 广东东阳光药业有限公司 Blood coagulation factor xia inhibitor and uses thereof
JOP20180025B1 (en) 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc Substituted indoline derivatives as dengue viral replication inhibitors
JOP20180026A1 (en) 2017-03-31 2019-01-30 Univ Leuven Kath Substituted indoline derivatives as dengue viral replication inhibitors
BR112019024311A2 (en) 2017-05-22 2020-07-28 Janssen Pharmaceuticals, Inc. substituted indoline derivatives as dengue viral replication inhibitors
US11407715B2 (en) 2017-05-22 2022-08-09 Janssen Pharmaceuticals, Inc. Substituted indoline derivatives as dengue viral replication inhibitors
WO2019011166A1 (en) * 2017-07-14 2019-01-17 四川科伦博泰生物医药股份有限公司 Macrocyclic amide compound, pharmaceutical composition and application thereof
CN119775276A (en) 2019-04-11 2025-04-08 百时美施贵宝公司 Novel synthetic options for preparing compounds
KR20210151183A (en) * 2019-04-11 2021-12-13 브리스톨-마이어스 스큅 컴퍼니 Enhanced Performance of Amorphous Solids and Solubilized Formulations to Achieve Therapeutic Plasma Concentrations
JP7270770B2 (en) * 2019-04-16 2023-05-10 チャイナ・リソースズ・バイオファーマシューティカル・カンパニー・リミテッド Macrocyclic derivatives as factor XIa inhibitors
CN114008047B (en) 2019-07-23 2023-03-21 南京明德新药研发有限公司 Macrocyclic derivatives as factor XIa inhibitors
TWI749881B (en) * 2019-11-21 2021-12-11 大陸商深圳信立泰藥業股份有限公司 Dioxopiperoid derivatives, their preparation method and their application in medicine
US20230151010A1 (en) * 2020-04-10 2023-05-18 Bristol-Myers Squibb Company Crystalline forms of (9r, 135s)-13- {4-[5-chloro-2-(4-chloro-1h,2,3- triazol- 1 -yl)phenyl] -6-oxo- 1,6-dihydropyrimidin- 1-yl}-3-(difluoromethyl)-9-methyl-3,4,7,15- tetraazatricyclo [ 12.3.1.0 2·6] octadeca- 1(18), 2(6), 4, 14, 16-pentaen-8-one
TW202229280A (en) * 2020-10-12 2022-08-01 美商必治妥美雅史谷比公司 A process toward the manufacture of (6r,10s)-10-{4-[5-chloro-2-(4-chloro-1h-1,2,3-triazol-1-yl)phenyl]-6-oxo-1(6h)-pyrimidinyl}- 1-(difluoromethyl)-6-methyl-1,4,7,8,9,10-hexahydro-11,15-(metheno)pyrazolo[4,3-b][1,7]diazacyclotetradecin-5(6h)-one
JP7517964B2 (en) * 2020-11-27 2024-07-17 シャープ株式会社 Electronic device, electronic device control method, program, and recording medium
CN112608274B (en) * 2020-12-30 2022-09-06 西南大学 Catalytic synthesis method of chiral amine compound and compound thereof
KR20230142724A (en) * 2021-01-08 2023-10-11 브리스톨-마이어스 스큅 컴퍼니 Antibodies and antigen-binding peptides against factor XIa inhibitors and uses thereof
CN112876461B (en) * 2021-01-20 2022-12-30 上海零诺生物科技有限公司 Process for the preparation of nicotine and intermediates therefor
CN115215867B (en) * 2021-04-21 2023-12-26 上海美悦生物科技发展有限公司 FXIa inhibitor, pharmaceutical composition, preparation method and application thereof
CN118973564A (en) * 2022-02-03 2024-11-15 D·E·萧尔研究有限责任公司 Pyridazinone compounds as TRPA1 inhibitors
JP2025524358A (en) * 2022-06-08 2025-07-30 ブロッサムヒル・セラピューティクス・インコーポレイテッド Indazole macrocycles and uses thereof
TW202515882A (en) * 2023-06-30 2025-04-16 大陸商深圳信立泰藥業股份有限公司 A polysubstituted macrocyclic compound and its preparation method and application
WO2025224678A1 (en) 2024-04-25 2025-10-30 Assia Chemical Industries Ltd. Solid state forms of milvexian and process for preparation thereof

Family Cites Families (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1525186A (en) 1967-03-29 1968-05-17 Roussel Uclaf New penicillins and method of preparation
DE3065190D1 (en) 1979-11-05 1983-11-10 Beecham Group Plc Enzyme derivatives, and their preparation
DE4034829A1 (en) 1990-11-02 1992-05-07 Merck Patent Gmbh CYCLOPEPTIDE
JP3190431B2 (en) 1991-07-01 2001-07-23 三菱化学株式会社 Ketone derivatives
GB9206757D0 (en) 1992-03-27 1992-05-13 Ferring Bv Novel peptide receptor ligands
US5624936A (en) 1995-03-29 1997-04-29 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
WO1996034010A2 (en) 1995-03-29 1996-10-31 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
AU717298B2 (en) 1996-04-03 2000-03-23 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5869682A (en) 1996-04-03 1999-02-09 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
PE121699A1 (en) 1997-02-18 1999-12-08 Boehringer Ingelheim Pharma BICYCLE HETERO CYCLES DISSTITUTED AS INHIBITORS OF THROMBIN
ZA985247B (en) 1997-06-19 1999-12-17 Du Pont Merck Pharma Guanidine mimics as factor Xa inhibitors.
TW557297B (en) 1997-09-26 2003-10-11 Abbott Lab Rapamycin analogs having immunomodulatory activity, and pharmaceutical compositions containing same
BRPI9909660B8 (en) 1998-03-19 2021-05-25 Vertex Pharma caspase inhibitor compounds, pharmaceutical composition and use of said compounds
CN1138778C (en) 1998-05-26 2004-02-18 沃尼尔·朗伯公司 Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidine sas inhibitors of cellular proliferation
US6307049B1 (en) 1998-09-30 2001-10-23 The Procter & Gamble Co. Heterocyclic 2-substituted ketoamides
EP1016663A1 (en) 1999-01-02 2000-07-05 Aventis Pharma Deutschland GmbH Novel malonic acid derivatives, processes for their preparation, their use and pharmaceutical compositions containing them (inhibition of factor Xa activity)
WO2000040571A1 (en) 1999-01-02 2000-07-13 Aventis Pharma Deutschland Gmbh Novel malonic acid derivatives, processes for their preparation, their use and pharmaceutical compositions containing them (inhibition of factor xa activity)
SK14232001A3 (en) 1999-04-09 2002-06-04 Basf Aktiengesellschaft Low-molecular inhibitors of complement proteases
WO2000076970A2 (en) 1999-06-14 2000-12-21 Eli Lilly And Company Serine protease inhibitors
DE19962924A1 (en) 1999-12-24 2001-07-05 Bayer Ag Substituted oxazolidinones and their use
EP1125925A1 (en) 2000-02-15 2001-08-22 Applied Research Systems ARS Holding N.V. Amine derivatives for the treatment of apoptosis
WO2001085695A1 (en) 2000-05-11 2001-11-15 Bristol-Myers Squibb Co. Tetrahydroisoquinoline analogs useful as growth hormone secretagogues
SV2003000617A (en) 2000-08-31 2003-01-13 Lilly Co Eli INHIBITORS OF PROTEASA PEPTIDOMIMETICA REF. X-14912M
AR035216A1 (en) 2000-12-01 2004-05-05 Astrazeneca Ab MANDELIC ACID DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE DERIVATIVES, USE OF THESE DERIVATIVES FOR THE MANUFACTURE OF MEDICINES, TREATMENT METHODS, PROCESSES FOR THE PREPARATION OF THESE DERIVATIVES, AND INTERMEDIARY COMPOUNDS
AU2002322802A1 (en) * 2001-07-27 2003-02-17 Merck And Co., Inc. Thrombin inhibitors
US6951840B2 (en) 2001-08-31 2005-10-04 Eli Lilly And Company Lipoglycopeptide antibiotics
ES2329881T3 (en) 2001-09-21 2009-12-02 Bristol-Myers Squibb Company COMPOUNDS CONTAINING LACTAMA AND DERIVATIVES OF THE SAME AS INHIBITORS OF FACTOR XA.
AU2002357692A1 (en) 2001-11-09 2003-05-26 Bristol-Myers Squibb Company Tetrahydroisoquinoline analogs as modulators of chemokine receptor activity
WO2003106438A1 (en) 2002-06-18 2003-12-24 The Scripps Research Institute Synthesis of diazonamide "a" core
US20040180855A1 (en) 2003-02-19 2004-09-16 Schumacher William A. Methods of treating thrombosis with reduced risk of increased bleeding times
US7138412B2 (en) 2003-03-11 2006-11-21 Bristol-Myers Squibb Company Tetrahydroquinoline derivatives useful as serine protease inhibitors
US7129264B2 (en) 2003-04-16 2006-10-31 Bristol-Myers Squibb Company Biarylmethyl indolines and indoles as antithromboembolic agents
JP2007501844A (en) 2003-08-08 2007-02-01 トランス　テック　ファーマ，インコーポレイテッド Aryl and heteroaryl compounds, compositions and methods of use
US7417063B2 (en) 2004-04-13 2008-08-26 Bristol-Myers Squibb Company Bicyclic heterocycles useful as serine protease inhibitors
US7453002B2 (en) 2004-06-15 2008-11-18 Bristol-Myers Squibb Company Five-membered heterocycles useful as serine protease inhibitors
US7429604B2 (en) 2004-06-15 2008-09-30 Bristol Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
EA200700225A1 (en) 2004-07-12 2008-02-28 Айдан Фармасьютикалз, Инк. TETRAPTIDE ANALOGUES
JP5236293B2 (en) 2005-01-13 2013-07-17 ブリストル−マイヤーズ スクイブ カンパニー Substituted biaryl compounds as XIA factor inhibitors
US20060183771A1 (en) 2005-02-17 2006-08-17 Seiffert Dietmar A Novel combination of selective factor VIIa and/or factor XIa inhibitors and selective plasma kallikrein inhibitors
US20070111947A1 (en) 2005-10-14 2007-05-17 Mcmurry Thomas J Fibrin targeted therapeutics
AU2006311101A1 (en) 2005-11-11 2007-05-18 F. Hoffmann-La Roche Ag Carbocyclic fused cyclic amines as inhibitors of the coagulation factor Xa
AR058379A1 (en) 2005-12-14 2008-01-30 Bristol Myers Squibb Co DERIVATIVES OF ARILPROPIONAMIDE ARILACRILAMIDA ARILPROPINAMIDA OR ARILMETILUREA AS INHIBITORS OF XIA FACTOR PROCESS OF OBTAINING AND PHARMACEUTICAL COMPOSITIONS.
WO2007070816A2 (en) 2005-12-14 2007-06-21 Bristol-Myers Squibb Company Thiophene derivatives as factor xia inhibitors
JP2009519966A (en) 2005-12-14 2009-05-21 ブリストル−マイヤーズ スクイブ カンパニー 6-membered heterocycles useful as serine protease inhibitors
AR058380A1 (en) 2005-12-23 2008-01-30 Bristol Myers Squibb Co INHIBITORS OF THE VIEW MACROCICLIC FACTOR USEFUL AS ANTICOAGULANTS
CN101389613B (en) * 2005-12-23 2011-10-12 布里斯托尔-迈尔斯.斯奎布公司 Macrocyclic factor viia inhibitors useful as anticoagulants
CN101605779B (en) 2006-12-15 2013-11-20 百时美施贵宝公司 Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors
PE20081775A1 (en) 2006-12-20 2008-12-18 Bristol Myers Squibb Co MACROCYCLIC COMPOUNDS AS INHIBITORS OF FACTOR VIIA
MX2009012847A (en) 2007-06-13 2009-12-08 Bristol Myers Squibb Co Dipeptide analogs as coagulation factor inhibitors.
CN102026996B (en) 2008-03-13 2015-01-07 百时美施贵宝公司 Pyridazine derivatives as factor XIA inhibitors
US8624040B2 (en) 2009-06-22 2014-01-07 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
US8513433B2 (en) 2009-07-02 2013-08-20 Angion Biomedica Corp. Small molecule inhibitors of PARP activity
AR077695A1 (en) 2009-08-04 2011-09-14 Schering Corp PIRIMIDINE DERIVATIVES AS INHIBITORS OF FACTOR IXA
EP2475654B1 (en) * 2009-09-09 2016-12-28 E. I. du Pont de Nemours and Company Herbicidal pyrimidone derivatives
CN102753555B (en) * 2010-02-11 2018-01-12 百时美施贵宝公司 Macrocycles as Factor XIA Inhibitors
US9161924B2 (en) 2011-07-08 2015-10-20 Merck Sharp & Dohme Corp. Factor IXa inhibitors
TW201311689A (en) * 2011-08-05 2013-03-16 必治妥美雅史谷比公司 Novel macrocyclic compounds as factor XIA inhibitors
TW201319068A (en) * 2011-08-05 2013-05-16 必治妥美雅史谷比公司 Cyclic P1 linkers as factor XIa inhibitors
EP2766347B1 (en) 2011-10-14 2016-05-04 Bristol-Myers Squibb Company Substituted tetrahydroisoquinoline compounds as factor xia inhibitors
EP3309148A1 (en) 2011-10-14 2018-04-18 Bristol-Myers Squibb Company Substituted tetrahydroisoquinoline compounds as factor xia inhibitors
EP2899183B1 (en) 2011-10-14 2018-09-19 Bristol-Myers Squibb Company Substituted Tetrahydroisoquinoline Compounds as Factor Xia Inhibitors
GB2497806A (en) 2011-12-21 2013-06-26 Ono Pharmaceutical Co Pyridinone and pyrimidinone derivatives as factor XIa inhibitors
EP2794597B1 (en) * 2011-12-21 2017-11-15 ONO Pharmaceutical Co., Ltd. Pyridinone and pyrimidinone derivatives as factor xia inhibitors
WO2013111108A1 (en) 2012-01-27 2013-08-01 Novartis Ag 5-membered heteroarylcarboxamide derivatives as plasma kallikrein inhibitors
WO2013111107A1 (en) 2012-01-27 2013-08-01 Novartis Ag Aminopyridine derivatives as plasma kallikrein inhibitors
JP2015083542A (en) 2012-02-08 2015-04-30 大日本住友製薬株式会社 Three substituted proline derivative
SG10201609322QA (en) 2012-05-10 2017-01-27 Bayer Pharma AG Antibodies capable of binding to the coagulation factor xi and/or its activated form factor xia and uses thereof
GB201209138D0 (en) 2012-05-24 2012-07-04 Ono Pharmaceutical Co Compounds
JP6220786B2 (en) 2012-07-19 2017-10-25 大日本住友製薬株式会社 1- (Cycloalkylcarbonyl) proline derivative
EA028581B1 (en) * 2012-08-03 2017-12-29 Бристол-Маерс Сквибб Компани DIHYDROPYRIDONE P1 AS FACTOR XIa INHIBITORS
UY34959A (en) 2012-08-03 2014-01-31 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware DIHYDROPIRIDONE P1 AS INHIBITORS OF THE XIA FACTOR
EP2906541B1 (en) 2012-10-12 2017-11-22 Bristol-Myers Squibb Company Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
DK2906551T3 (en) 2012-10-12 2018-05-22 Bristol Myers Squibb Co CRYSTALLIC FORMS OF A FACTOR XIA INHIBITOR
WO2014059202A1 (en) 2012-10-12 2014-04-17 Bristol-Myers Squibb Company Guanidine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
EP2934538B1 (en) 2012-12-19 2021-03-31 Merck Sharp & Dohme Corp. Factor ixa inhibitors
GB201300304D0 (en) 2013-01-08 2013-02-20 Kalvista Pharmaceuticals Ltd Benzylamine derivatives
GB2510407A (en) 2013-02-04 2014-08-06 Kalvista Pharmaceuticals Ltd Aqueous suspensions of kallikrein inhibitors for parenteral administration
US9738655B2 (en) 2013-03-25 2017-08-22 Bristol-Myers Squibb Company Tetrahydroisoquinolines containing substituted azoles as factor XIa inhibitors
TWI633089B (en) 2013-03-28 2018-08-21 拜耳製藥股份有限公司 Substituted oxopyridine derivatives
CN105555767B (en) 2013-07-23 2018-03-23 拜耳制药股份公司 Substituted oxo pyridine derivative and its purposes as factor XI, plasma thromboplastin antecedent A/ blood plasma
WO2015044173A1 (en) 2013-09-26 2015-04-02 Bayer Pharma Aktiengesellschaft Substituted phenylalanine derivatives as modulators of factor xia
EP3049403A1 (en) 2013-09-26 2016-08-03 Bayer Pharma Aktiengesellschaft Substituted phenylalanine derivatives
WO2015044167A1 (en) 2013-09-26 2015-04-02 Bayer Pharma Aktiengesellschaft Substituted phenylalanine derivatives as modulators of factor xia
UY35745A (en) 2013-09-26 2015-04-30 Bayer Pharma AG SUBSTITUTED DERIVATIVES OF PHENYLALANINE
EP3049406A1 (en) 2013-09-26 2016-08-03 Bayer Pharma Aktiengesellschaft Substituted phenylalanine derivatives and use thereof to treat thrombotic/thromboembolic diseases
EP3049407A1 (en) 2013-09-26 2016-08-03 Bayer Pharma Aktiengesellschaft Substituted phenylalanine derivatives as modulators of factor xia
UY35746A (en) 2013-09-26 2015-04-30 Bayer Pharma AG SUBSTITUTED PHENYLALANINE DERIVATIVES
EP3049408A1 (en) 2013-09-26 2016-08-03 Bayer Pharma Aktiengesellschaft Substituted phenylalanine derivatives
US20160229839A1 (en) 2013-09-27 2016-08-11 Merck Sharp & Dohme Corp. Factor XIa Inhibitors
WO2015054087A1 (en) 2013-10-07 2015-04-16 Merck Sharp & Dohme Corp. FACTOR XIa INHIBITORS
JP6337750B2 (en) 2013-11-22 2018-06-06 小野薬品工業株式会社 Compound
KR20160107322A (en) 2014-01-14 2016-09-13 다이닛본 스미토모 세이야꾸 가부시끼가이샤 Condensed 5-oxazolidinone derivative
NO2760821T3 (en) 2014-01-31 2018-03-10
UY40230A (en) * 2014-01-31 2023-08-15 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Macrocycles with heterocyclic P2' groups as inhibitors of factor XIa and pharmaceutical compositions comprising them
EP3102200B1 (en) 2014-02-07 2023-04-05 Exithera Pharmaceuticals Inc. Therapeutic compounds and compositions
WO2015123091A1 (en) 2014-02-11 2015-08-20 Merck Sharp & Dohme Corp. Factor xia inhibitors
EP3104703B1 (en) 2014-02-11 2020-11-18 Merck Sharp & Dohme Corp. Factor xia inhibitors
EP3104701B1 (en) 2014-02-11 2019-01-30 Merck Sharp & Dohme Corp. Factor xia inhibitors
CN105829298B (en) 2014-02-14 2019-02-01 四川海思科制药有限公司 A kind of pyridone or pyrimidinone derivative, its preparation method and application
PT3113772T (en) 2014-03-07 2020-12-15 Biocryst Pharm Inc Human plasma kallikrein inhibitors
WO2015160636A1 (en) 2014-04-16 2015-10-22 Merck Sharp & Dohme Corp. Factor ixa inhibitors
US9808445B2 (en) 2014-04-16 2017-11-07 Merck Sharp & Dohme Corp. Factor IXa inhibitors
GB201409202D0 (en) * 2014-05-23 2014-07-09 Ffei Ltd Improvements in imaging microscope samples
KR20150136294A (en) 2014-05-27 2015-12-07 주식회사 레고켐 바이오사이언스 New Compound Having Inhibition Activity to Factor XIa
EP3148542B1 (en) 2014-05-28 2019-02-27 Merck Sharp & Dohme Corp. Factor xia inhibitors
WO2016046157A1 (en) 2014-09-24 2016-03-31 Bayer Pharma Aktiengesellschaft Factor xia-inhibiting pyridobenzazepine and pyridobenzazocine derivatives
US9453018B2 (en) * 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
NO2721243T3 (en) * 2014-10-01 2018-10-20
EP3231803B1 (en) 2014-12-10 2020-07-01 ONO Pharmaceutical Co., Ltd. Dihydroindolizinone derivative
EP3310777B1 (en) 2015-06-19 2019-10-09 Bristol-Myers Squibb Company Diamide macrocycles as factor xia inhibitors

Also Published As

Publication number Publication date
CN105980384A (en) 2016-09-28
HRP20181339T1 (en) 2018-12-28
RS57659B1 (en) 2018-11-30
AU2019216617A1 (en) 2019-09-05
AU2023203695A1 (en) 2023-07-06
AU2015210904B2 (en) 2019-05-16
IL272377B2 (en) 2023-05-01
MX2016009230A (en) 2016-10-03
BR112016015717A8 (en) 2018-05-02
MY190429A (en) 2022-04-21
TW201615639A (en) 2016-05-01
IL246964B (en) 2020-02-27
PH12016501249B1 (en) 2022-01-21
PE20210470A1 (en) 2021-03-08
TW201613922A (en) 2016-04-16
KR102413453B1 (en) 2022-06-28
JP6505727B2 (en) 2019-04-24
UY40230A (en) 2023-08-15
LT3099687T (en) 2018-09-10
CA2937739C (en) 2024-04-16
WO2015116886A1 (en) 2015-08-06
ES2784841T3 (en) 2020-10-01
TWI688564B (en) 2020-03-21
EP3099687A1 (en) 2016-12-07
AU2019216617B2 (en) 2021-03-18
EP3099686A1 (en) 2016-12-07
JP6854067B2 (en) 2021-04-07
PH12021550418A1 (en) 2021-11-15
NZ761182A (en) 2023-04-28
UY35975A (en) 2015-07-31
IL307212A (en) 2023-11-01
MX2020012520A (en) 2021-02-16
TWI859674B (en) 2024-10-21
TW202037595A (en) 2020-10-16
UY35971A (en) 2015-07-31
DK3099687T3 (en) 2018-10-22
SG10201908467RA (en) 2019-10-30
KR102631769B1 (en) 2024-02-01
IL298983B2 (en) 2024-03-01
KR20220093390A (en) 2022-07-05
JP2021088610A (en) 2021-06-10
US9777001B2 (en) 2017-10-03
EA201691471A1 (en) 2016-12-30
PH12016501249A1 (en) 2016-08-15
ZA201606011B (en) 2018-05-30
NZ723762A (en) 2023-03-31
MX377545B (en) 2025-03-10
ES2893251T3 (en) 2022-02-08
PE20161069A1 (en) 2016-10-22
IL298983B1 (en) 2023-11-01
JP2019077704A (en) 2019-05-23
SI3099687T1 (en) 2018-08-31
AU2021203968B2 (en) 2023-03-30
EP3988549A1 (en) 2022-04-27
EP3099687B1 (en) 2018-07-04
IL298983A (en) 2023-02-01
EP3099686B1 (en) 2020-03-11
SMT201800505T1 (en) 2018-11-09
EA030222B1 (en) 2018-07-31
JP6630004B2 (en) 2020-01-15
PT3099687T (en) 2018-10-19
CN116987080A (en) 2023-11-03
WO2015116885A1 (en) 2015-08-06
CN105980384B (en) 2019-11-15
AU2015210904A1 (en) 2016-09-15
AU2025201886A1 (en) 2025-04-03
CY1120702T1 (en) 2019-12-11
BR112016015717B1 (en) 2023-04-04
JP6464176B2 (en) 2019-02-06
CL2016001933A1 (en) 2017-03-24
US20170002006A1 (en) 2017-01-05
EP3392249B1 (en) 2021-08-25
JP2017504642A (en) 2017-02-09
JP2023133468A (en) 2023-09-22
KR20240017118A (en) 2024-02-06
IL272377B1 (en) 2023-01-01
IL272377A (en) 2020-03-31
EP3392249A1 (en) 2018-10-24
HUE040226T2 (en) 2019-02-28
ES2687498T3 (en) 2018-10-25
CN110845498A (en) 2020-02-28
CN106132962B (en) 2018-09-07
JP2017504641A (en) 2017-02-09
AU2015210904C1 (en) 2019-08-29
PL3099687T3 (en) 2018-12-31
US20170096429A1 (en) 2017-04-06
TW202340188A (en) 2023-10-16
TWI790421B (en) 2023-01-21
CN106132962A (en) 2016-11-16
JP7325464B2 (en) 2023-08-14
CN110845498B (en) 2023-02-17
JP2019094354A (en) 2019-06-20
KR20160113267A (en) 2016-09-28
IL322255A (en) 2025-09-01
IL246964A0 (en) 2016-09-29
CA2937739A1 (en) 2015-08-06
AU2021203968A1 (en) 2021-07-08
BR112016015717A2 (en) 2017-08-08

Similar Documents

Publication Publication Date Title
ZA201606011B (en) Macrocycles with hetrocyclic p2' groups as factor xia inhibitors
IL291598A (en) Cytotoxic benzodiazepine derivatives
IL251976A0 (en) טיפול פאג'י
PL3359543T3 (en) Cucurbituril derivatives
GB2540892B (en) Pyrrolobenzodiazepine compounds
GB2530076B (en) Injector pens
GB2524785B8 (en) Injector mount
GB201414116D0 (en) Benzodiazepine derivatives
HUE038233T2 (en) Pouch with slide-in pocket
IL258430B (en) Anti-tumoral composition
GB2523854B (en) Circuitry
PL2992779T3 (en) Multi-configuration furniture
GB201416351D0 (en) Heterocyclic derivatives
GB201420497D0 (en) Pants with pockets
GB201510929D0 (en) Laminate pouches
GB201420324D0 (en) Don't get flirty with thirty
GB201417515D0 (en) 247 snooker
GB201401354D0 (en) Laminating pouches
AU357971S (en) Furnishing
AU357970S (en) Furnishing
AP00748S1 (en) Desks
PH32014000260S1 (en) Pocket cell (01)
PH32014000070S1 (en) Injector